TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Diagnosed with B-CLL/SLL based on the standard histologic and immunophenotypic criteria described in the WHO classification~* No prior systemic therapy for CLL/SLL, including chemotherapy or antibody therapy~* Currently needs therapy based on 1996 NCI-WG criteria~* Measurable disease~* ECOG Performance Status of 0-2~* Laboratory test results within parameters outlined in protocol~* Able to take aspirin daily as prophylactic anticoagulation~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent document~* Pregnant or breast-feeding females~* Any condition, including the presence of abnormal laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study~* Use of any other experimental drug or therapy within 28 days of baseline~* Known hypersensitivity to thalidomide~* Development of erythema nodosum characterized by a desquamating rash while taking thalidomide or similar drugs~* Prior use of lenalidomide~* Concurrent use of other anti-cancer agents or treatments~* Known positive for HIV~* Chronic active Hep B patients not on prophylactic lamivudine~* Diagnosis of Mantle Cell Lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide, fludarabine and rituximab (Type: EXPERIMENTAL): Lenalidomide-Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period fludarabine- Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days Rituximab- Given intravenously on Day 1 of each 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Pyridostigmine in Pompe Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females between 8 and 60 years of age;~2. Diagnosis of Pompe disease (protein assay, genotyping, and positive clinical signs)~3. No contraindication to pyridostigmine~Exclusion Criteria:~1. Already receive pyridostigmine as part of their normal clinical care at screening~2. Are pregnant - participants will receive a urine pregnancy test at screening~3. Have received acute administration of antibiotic, corticosteroid, or neuromuscular blockade medications within 30 days prior to screening~4. Any other concurrent medical condition which, in the opinion of the study team, would make the subject inappropriate to participate in the assessments

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Acute Dose of Pyridostigmine (Type: EXPERIMENTAL): Subjects will receive an acute administration of pyridostigmine bromide, calculated on their body weight at clinical exam (1 mg/kg, 60mg max starting dose), and will be monitored for 2 hours post administration. Subjects will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm.
- Prolonged Use of Pyridostigmine (Type: EXPERIMENTAL): This arm will evaluate the impact of pyridostigmine bromide on respiratory and skeletal muscle function during a 90-day administration period. On Days 1 - 7 subjects will receive 0.5mg/kg of the study drug every 4 hours while awake. On Days 8 - 90 subjects will receive 1.0 mg/kg every 4 hours while awake. Quality of life will also be measured with the SF-36 health survey. Data collection will occur at multiple time points (Days 30 and 90) throughout the study. Subjects will also be contacted at least weekly via telephone. All study subjects will be enrolled in this arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed advanced, recurrent, or metastatic colorectal adenocarcinoma~* Resected CNS metastases stable greater than 1 month after completion of radiotherapy for CNS metastases eligible~  * No existing CNS metastases allowed~* Measurable disease~  * At least 1 dimension as at least 20 mm with conventional techniques OR~ * At least 10 mm with spiral CT scan~ * No truly nonmeasurable lesions:~    * Bone lesions~   * Leptomeningeal disease~   * Lymphangitis cutis/pulmonis~   * Abdominal masses not confirmed and followed by imaging techniques~   * Cystic lesions~* Must have progressed on at least 1 prior, but no more than 2 prior, fluorouracil and/or irinotecan containing treatment regimens for metastatic colorectal cancer~* Must have documented HER-2/neu overexpression by immunohistochemistry staining~  * Staining score at least 2+~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 1,500/mm3~* Platelet count at least 100,000/mm3~Hepatic:~* Bilirubin no greater than 2.0 mg/dL~* AST no greater than 2.5 times upper limit of normal~Renal:~* Creatinine normal OR~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No history of cardiac ischemia or congestive heart failure~* LVEF at least 50% by ECG or MUGA~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No concurrent second malignancy except nonmelanoma skin cancers or carcinoma in situ of the cervix unless completed therapy and considered to be at less than 30% risk of relapse~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* No prior platinum containing chemotherapy~* At least 3 weeks since prior chemotherapy and recovered~* No other concurrent chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 3 weeks since prior radiotherapy and recovered~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Chemotx (Type: EXPERIMENTAL): Combination chemotherapy for metastatic colorectal cancer in patients who have disease progression after 5-FU and/or irinotecan-containing therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Osteoarthritis Shoulder Injection Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* An X-ray within a year with Radiographic evidence of OA~* 18 years of age or older~* Clinical diagnosis established due to symptoms that will include pain attributed to glenohumeral osteoarthritis, pain with range of motion, and/or functional limitations longer than 3 months.~Exclusion Criteria:~* Previous guided steroid injection of the glenohumeral joint within 3 months~* Previous diagnosis of inflammatory arthritis, rotator cuff tear, or immunocompromised~* Previous shoulder surgery~* Allergy to steroid or lidocaine~* A Kellgren and Lawrence classification of 1 or less on radiograph~* Non-English Speaking~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 20 mg Triamcinolone with 3cc of 1% Lidocaine (Type: ACTIVE_COMPARATOR): 20mg Triamcinolone with 3cc of 1% Lidocaine
- 40 mg Triamcinolone with 3cc of 1% Lidocaine (Type: ACTIVE_COMPARATOR): 40mg Triamcinolone with 3cc of 1% Lidocaine
- 80 mg Triamcinolone with 3cc of 1% Lidocaine (Type: ACTIVE_COMPARATOR): 80mg Triamcinolone with 3cc of 1% Lidocaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin in Pediatric Patients With Bacterial Meningitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 3 months and \< 16 years~* Bacterial meningitis~* Written parental (or appropriate legal representative) informed consent prior to study inclusion~Exclusion Criteria~* Gram-negative bacteria in the CSF~* Creatinine clearance \< 80ml/min/1.73m2~* Creatinine phosphokinase level \> 2x upper age related norm~* Known allergy or hypersensitivity to daptomycin~* Known clinical significant cardiovascular, pulmonary, renal, hepatic, gastrointestinal, endocrine, hematologic, autoimmune disease, or primary immunodeficiency~* Height and weight below 3rd or above 95th percentile~* History of, or current muscular disease~* Underlying neurological disease with disruption of blood brain barrier~* Epilepsy~* Muscular weakness, history of peripheral neuropathy, or Guillain-Barré syndrome

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): i.v. daptomycin given 24 hours after first ceftriaxone dose at age appropriate dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be at least 18 years of age;~* Patients must be able to provide informed consent;~* Histologically proven low-grade or intermediate-grade prostate cancer (PC)~* Scheduled to undergo targeted local therapy (HDR brachytherapy).~Exclusion Criteria:~* Inability to lie still for the entire imaging time;~* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.);~* Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance;~* Metallic implants (contraindicated for MRI).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 68Ga-RM2 PET MRI then 68 Ga PMSA11 PET/MRI (Type: EXPERIMENTAL): Subjects will undergo either 68Ga RM2 PET/MRI followed within 2 weeks by 68Ga PMSA11 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
- 68Ga-PSMA-11 PET MRI then 68Ga-RM2 PET MRI (Type: EXPERIMENTAL): Subjects will undergo 68Ga PMSA11 PET/MRI followed within 2 weeks by 68Ga RM2 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Parasitologically confirmed, primarily ulcerative, Old World CL, in a patient who had either failed pentavalent antimony treatment, or who was ineligible for pentavalent antimony therapy.~* Military health care beneficiary 18 years of age or greater, unless active military in which case, 17 years is the minimum age~* Proven parasitological diagnosis by culture, PCR or microscopy in at least one skin lesion~* Lesions primarily ulcerative (i.e., not verrucous or nodular)~* Written informed consent to participate in protocol~* Negative pregnancy test within 72 hours of starting protocol~* Agrees to take precautions not to become pregnant or father a child for at least two months after completion of treatment with WR 279,396~* Cutaneous leishmaniasis acquired in Southwest Central Asia/Middle East\*~* Inadequate response to treatment with pentavalent antimony or medical condition that precludes the use of pentavalent antimony~Exclusion Criteria:~* Drug intolerance: history of known or suspected hypersensitivity or idiosyncratic reactions to aminoglycosides in the patient~* any leishmanial lesion on mucosal surface~* Presence of signs or symptoms of peripheral neuropathic myasthenia gravis, neuromuscular block~* Routinely taking nephrotoxic or ototoxic medications~* Disseminated disease defined as clinically significant subcutaneous nodules that are in the lymphatic drainage tract for the skin lesion with regional adenopathy \> 1 cm~* Abnormal Romberg test at baseline~* Clinically significant medical problems of the kidney or liver as determined by history and by the following laboratory studies:~  * Kidney: Creatinine \> 2x the upper limit of normal~ * Liver: ASTor ALT \>4x the upper limit fo normal~    * This includes L. major, L. tropica, and L. infantum with over 98% of cases in U.S. military in 2002-2004 being L. major~      * An inadequate response to treatment with pentavalent antimony includes patients who show no or little improvement during a 15-20 day treatment course, those that initially epithelialize but later show signs of breakdown/ ulceration or develop new lesions. In general, for those with initial treatment response, would recommend waiting for approximately two months after pentavalent antimony and if lesion is not epithelialized at that time, consideration for further therapy is advised.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paromomycin +Gentamicin topical cream (Type: EXPERIMENTAL): WR279,396 topically twice a day for 20 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Age 60 years or older~* Measurable non-metastatic and non-inflammatory breast cancer~* Tumor of 2 cm or larger~* ER and/or PgR positive tumor~* Co-morbidity index 0 - 3, e.g., no other serious medical condition~Exclusion Criteria:~* Prior medical therapy for a malignant disease, including aromatase inhibitors~* Distant metastasis~* Need for chemotherapy~* Past or current history of other neoplasms (except for curative treated basal skin cancer or in situ carcinoma of the cervix uteri)~* Treatment with a non-approved drug within 30 days

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Postoperative letrozole (Type: ACTIVE_COMPARATOR): Definitive surgery without preoperative AI treatment
- Preoperative letrozole (Type: EXPERIMENTAL): Treatment with letrozole for 4 months before definitive surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Vaccination in Rheumatic Disease Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Rheumatologist confirmed diagnosis of one of the following diagnoses:~* Systemic lupus erythematosus;~* Sjogren syndrome;~* Inflammatory myositis;~* Psoriatic arthritis;~* Osteoarthritis;~* Gout;~* Ankylosing spondylitis;~* IBD-related arthritis.~Exclusion Criteria:~* Active infection or untreated malignancy (other than skin cancer) at enrollment.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mRNA COVID19 vaccines (Type: OTHER): mRNA-based COVID19 vaccines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Goal Directed Fluid Therapy Versus Liberal Fluid Regimen in Primary Elective Hip Artrhoplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50-80 years~* ASA I, II or III~* primary elective hip arthroplasty~Exclusion Criteria:~* spinal anesthesia contraindications~* periferical vasculopaty~* other diseases which indicates better an invasive monitoring by radial artery cannulation~* atrial fibrillation~* denial or inability to provide informed consent

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Clearsight (Type: EXPERIMENTAL): hemodynamic monitoring and goal directed fluid therapy guided by clearsight
- Control (Type: OTHER): hemodynamic monitoring blinded and silenced, no goal directed fluid therapy. Fluid therapy based on clinical evaluation and mean arterial pressure by non-invasive monitoring

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All patients age 18 years and older with typical trigeminal neuralgia, as determined by diagnostic criteria set by the International Headache Society, who are:~* Intolerant of or refractory to medical management; AND~* Not candidates for or refusing a surgical micro-vascular decompression.~Exclusion Criteria:~* Patients who present with pre-existing BNI grade III or IV facial numbness.~* Patients who have previously been treated with MVD.~* Patients who have previously had an ablative treatment, including prior SRS.~* Pediatric patients (age \<18), pregnant women, and patients who are unable to give informed consent will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo and SRS
- Amifostine (Type: EXPERIMENTAL): Amifostine and CyberKnife stereotactic radiosurgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical history of perennial allergic rhinitis and a positive skin prick test to dust mite, cockroach, mold, or cat or dog antigens.~* Willingness of the subject to participate in and complete the study, and the ability to understand the purpose of the trial.~Exclusion Criteria:~* Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.~* Women of childbearing potential who are pregnant, trying to become pregnant or nursing a child.~* Subjects treated with systemic steroids during the previous 30 days.~* Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 15 days.~* Subjects treated with oral antihistamines/decongestants during the previous seven days.~* Subjects treated with topical (intranasal or intraocular) antihistamines/decongestants during the previous 3 days.~* Subjects treated with immunotherapy who are escalating their dose.~* Subjects on chronic anti-asthma medications.~* Subjects with polyps in the nose or a significantly displaced septum.~* Subjects who have incurred an upper respiratory tract infection within 14 days of the start of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Fluticasone propionate + Placebo (Type: PLACEBO_COMPARATOR): Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Placebo - 10 mg po daily for 2 weeks
- Fluticasone propionate + Montelukast (Type: ACTIVE_COMPARATOR): Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Montelukast - 10 mg po daily for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues